Abstract
Purpose
Synchronous bilateral breast cancer is uncommon, and its pattern and incidence among younger women is unknown. Here we report the incidence, phenotypes, and long-term oncologic outcomes of bilateral breast cancer in women enrolled in the Young Women’s Breast Cancer Study (YWS).
Methods
The YWS is a multi-center, prospective cohort study of women with breast cancer diagnosed at age ≤ 40 years. Those with synchronous bilateral breast cancer formed our study cohort. Tumor phenotypes were categorized as luminal A (hormone receptor (HR)+/HER2−/grade 1/2), luminal B (HR+ /HER2+ or HER2− and grade 3), HER2-enriched (HR−/HER2+), or basal-like (HR−/HER2−). Descriptive statistics were used to evaluate tumor phenotypes of bilateral cancers for concordance.
Results
Among 1302 patients enrolled in the YWS, 21 (1.6%) patients had synchronous bilateral disease. The median age of diagnosis was 38 years (range 18–40 years). Seventeen (81.0%) underwent genetic testing with 6 found to have pathogenic germline mutations in BRCA1, BRCA2, or TP53. The majority of patients (76.2%) underwent bilateral mastectomy. On pathology, 2 patients had bilateral in-situ disease, 6 had unilateral invasive and contralateral in-situ disease, and 13 had bilateral invasive disease. Of those with bilateral invasive disease, 10 (76.9%) had bilateral luminal tumors and, when fully characterized, 6 were of the same luminal subtype. Only 1 patient had bilateral basal-like breast cancer. At median follow-up of 8.2 years, 14 patients are alive with no recurrent disease.
Conclusions
Bilateral breast cancer is uncommon among young women diagnosed with breast cancer at age ≤ 40. In our cohort, the majority of invasive tumors were of the luminal phenotype, though some differed by grade or HER2 status. These findings support the need for thorough pathologic workup of bilateral disease when it is found in young women with breast cancer to determine risk and tailor treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
de la Rochefordiere A, Asselain B, Scholl S, Campana F, Ucla L, Vilcoq JR, Durand JC, Pouillart P, Fourquet A (1994) Simultaneous bilateral breast carcinomas: a retrospective review of 149 cases. Int J Radiat Oncol Biol Phys 30(1):35–41. https://doi.org/10.1016/0360-3016(94)90516-9
Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM (2000) Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 88(12):2739–2750
Sakai T, Ozkurt E, DeSantis S, Wong SM, Rosenbaum L, Zheng H, Golshan M (2019) National trends of synchronous bilateral breast cancer incidence in the United States. Breast Cancer Res Treat 178(1):161–167. https://doi.org/10.1007/s10549-019-05363-0
Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, Dickman PW, Hall P (2007) Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 25(27):4210–4216. https://doi.org/10.1200/jco.2006.10.5056
Ruddy KJ, Gelber SI, Tamimi RM, Ginsburg ES, Schapira L, Come SE, Borges VF, Meyer ME, Partridge AH (2014) Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 32(11):1151–1156. https://doi.org/10.1200/jco.2013.52.8877
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206–2223. https://doi.org/10.1093/annonc/mdt303
Rosenberg SM, Greaney ML, Patenaude AF, Partridge AH (2019) Factors affecting surgical decisions in newly diagnosed young women with early-stage breast cancer. J Adolescent Young Adult Oncol 8(4):463–468. https://doi.org/10.1089/jayao.2019.0002
Kheirelseid EA, Jumustafa H, Miller N, Curran C, Sweeney K, Malone C, McLaughlin R, Newell J, Kerin MJ (2011) Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics. Breast Cancer Res Treat 126(1):131–140. https://doi.org/10.1007/s10549-010-1057-y
Baykara M, Ozturk SC, Buyukberber S, Helvaci K, Ozdemir N, Alkis N, Berk V, Koca D, Coskun U, Oksuzoglu B, Uncu D, Arpaci E, Ustaalioglu BO, Demirci U, Kucukoner M, Dogu GG, Alici S, Akman T, Ozkan M, Aslan UY, Durnali AG, Benekli M (2012) Clinicopathological features in bilateral breast cancer. Asian Pac J Cancer Prev 13(9):4571–4575
Rosenberg SM, Ruddy KJ, Tamimi RM, Gelber S, Schapira L, Come S, Borges VF, Larsen B, Garber JE, Partridge AH (2016) BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol 2(6):730–736. https://doi.org/10.1001/jamaoncol.2015.5941
Narod SA (2014) Bilateral breast cancers. Nat Rev Clin Oncol 11(3):157–166. https://doi.org/10.1038/nrclinonc.2014.3
Sandberg ME, Hartman M, Klevebring D, Eloranta S, Ploner A, Hall P, Czene K (2012) Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer. Breast Cancer Res Treat 134(2):793–800. https://doi.org/10.1007/s10549-012-2096-3
Coradini D, Oriana S, Mariani L, Miceli R, Bresciani G, Marubini E, Di Fronzo G (1998) Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur J Cancer 34(6):825–830. https://doi.org/10.1016/s0959-8049(97)10121-6
Begg CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, Ng CKY, Sakr RA, Bernstein JL, Burke KA, King TA, Piscuoglio S, Mauguen A, Orlow I, Weigelt B, Seshan VE, Morrow M, Reis-Filho JS (2018) Contralateral breast cancers: Independent cancers or metastases? Int J Cancer 142(2):347–356. https://doi.org/10.1002/ijc.31051
Packwood K, Martland G, Sommerlad M, Shaw E, Moutasim K, Thomas G, Bateman AC, Jones L, Haywood L, Evans DG, Birch JM, Alsalmi OA, Henderson A, Poplawski N, Eccles DM (2019) Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study). J Pathol Clin Res 5(3):189–198. https://doi.org/10.1002/cjp2.133
Kuba MG, Lester SC, Bowman T, Stokes SM, Taneja KL, Garber JE, Dillon DA (2020) Histopathologic features of breast cancer in Li-Fraumeni syndrome. Mod Pathol. https://doi.org/10.1038/s41379-020-0610-4
Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684–1691. https://doi.org/10.1200/jco.2009.24.9284
Guzman-Arocho YD, Rosenberg SM, Poorvu P, Ruddy KJ, Kirkner G, Snow C, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Warner E, Partridge AH, Collins LC (2020) Abstract P4-07-02: clinicopathological features and BRCA 1/2 status in a large prospective cohort of young women with breast cancer. https://cancerres.aacrjournals.org/content/80/4_Supplement/P4-07-02.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Research involving human participants
The YWS was approved by the Institutional Review Board at Dana-Farber Cancer Institute and other participating sites.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Pak, L.M., Gaither, R., Rosenberg, S.M. et al. Tumor phenotype and concordance in synchronous bilateral breast cancer in young women. Breast Cancer Res Treat 186, 815–821 (2021). https://doi.org/10.1007/s10549-020-06027-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-020-06027-0